Ontology highlight
ABSTRACT:
SUBMITTER: Isakoff SJ
PROVIDER: S-EPMC5618936 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature
Future oncology (London, England) 20161014 4
Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer. Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors. We describe herein the design and rationale of a Phase II trial investigatin ...[more]